Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) have been assigned an average rating of "Reduce" from the twelve analysts that are currently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a sell rating and seven have given a hold rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $23.42.
Several equities research analysts have issued reports on the stock. Berenberg Bank set a $24.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, September 29th. BNP Paribas Exane lowered shares of Fresenius Medical Care AG & Co. KGaA from a "neutral" rating to an "underperform" rating and set a $19.90 price objective for the company. in a research report on Tuesday, July 28th. Barclays downgraded shares of Fresenius Medical Care AG & Co. KGaA from an "equal weight" rating to an "underweight" rating in a research note on Monday, November 9th. Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA from a "hold" rating to a "strong sell" rating in a report on Thursday, October 15th. Finally, Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday, October 8th.
Read Our Latest Stock Report on Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA Stock Down 0.8%
Shares of NYSE:FMS opened at $21.85 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.69 and a current ratio of 0.99. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $20.02 and a 1 year high of $26.42. The stock has a market capitalization of $11.63 billion, a P/E ratio of 8.12, a PEG ratio of 4.99 and a beta of 0.78. The stock has a 50-day simple moving average of $22.28 and a 200-day simple moving average of $22.90.
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported $0.64 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.65 by ($0.01). Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.08% and a net margin of 4.23%. The business had revenue of $5.59 billion for the quarter, compared to analyst estimates of $5.52 billion. Equities analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.23 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 39.1% during the third quarter. Farther Finance Advisors LLC now owns 1,915 shares of the company's stock worth $43,000 after purchasing an additional 538 shares in the last quarter. Pathstone Holdings LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 1.0% in the third quarter. Pathstone Holdings LLC now owns 70,345 shares of the company's stock valued at $1,630,000 after buying an additional 707 shares in the last quarter. Allworth Financial LP grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% in the second quarter. Allworth Financial LP now owns 3,552 shares of the company's stock valued at $80,000 after buying an additional 850 shares in the last quarter. Parallel Advisors LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 27.9% in the first quarter. Parallel Advisors LLC now owns 4,632 shares of the company's stock valued at $104,000 after buying an additional 1,011 shares in the last quarter. Finally, Trek Financial LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 9.2% in the third quarter. Trek Financial LLC now owns 12,350 shares of the company's stock valued at $276,000 after buying an additional 1,040 shares in the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.
About Fresenius Medical Care AG & Co. KGaA
(
Get Free Report)
Fresenius Medical Care AG & Co. KGaA is a healthcare company focused on treating people with chronic kidney failure. It provides dialysis care through a global network of treatment centers and supports patients who receive care in clinics or at home. The company also develops and supplies products used in dialysis, including dialysis machines, dialyzers, and related medical equipment and materials. Its services include clinical care and support for healthcare providers involved in kidney treatment.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fresenius Medical Care AG & Co. KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care AG & Co. KGaA wasn't on the list.
While Fresenius Medical Care AG & Co. KGaA currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.